ZEISS Microscope has been Optimized for Capturing Subcellular Structures and their Dynamics

Live imaging with uniform super-resolution in all spatial dimensions.

High-tech companies are increasingly focusing on health

Tech companies have been taking an interest in healthcare for many years, and this interest seems to be increasing. “It’s not a sudden shift in trend, it’s more...

Radioactive tracer to measure effect of drug towards Crohn’s disease

A radioactive tracer developed by Astra Zeneca and the Karolinska Institutet may play a major role for patients with Crohn's disease. That is the belief of Mari...

Nanexa finalist i Fierce Innovation Awards

Uppsalabolaget Nanexa har utsetts till finalist i den internationella tävlingen Fierce Innovation Awards Life Sciences. Bolaget uppmärksammas i kategorin Drug D...

Revealing the secrets of a part

CT inspection in automation technology at Festo.

Elevating 3D characterization with enhanced performance and efficiencies

Introducing the ZEISS VersaXRM 730 3D X-ray microscope.

Explore the latest trends and innovations in quality assurance and manufacturing

ZEISS QUALITY INNOVATION SUMMIT in Berlin, October 22-24, 2024.

Forskaren in Hagastaden now inagurated

The real estate company Vectura's life science center in Hagastaden, Forskaren, is now inaugurated. The opening was attended by people from the industry, politi...

Fast Optical Sectioning of Developing Organisms and Tissue Microstructures

ZEISS Lattice SIM 3 exploits the full potential of the SIM Apotome technology.

Grönt ljus för diabetespiller för att reducera hjärtrisker

FDA godkänner Novo Nordisks Rybelsus för behandling av allvarliga hjärt-kärlhändelser hos vuxna med typ 2-diabetes. Det är första gången ett oralt GLP-1-läkemed...

Clinigen Clinical Supplies Management GmbH

Microscope and measuring machine in one

ZEISS O-INSPECT duo covers two essential applications in quality assurance.

Festo Expands its Portfolio with Multilayer Manifolds

Manufacturers of medical and laboratory equipment now receive solutions from a single source

Join the premier metrology and quality assurance event of the year

ZEISS QUALITY INNOVATION SUMMIT in Berlin, October 22-24, 2024.

Vaccinbolag backade när Trump nominerade vaccinskeptiker

Flera av de stora vaccinbolagen föll på börsen efter att vaccinskeptikern Robert F. Kennedy Jr. på torsdagen nominerats till posten som hälsominister i Donald T...

EMA review confirms a risk of new cancer after CAR-T

CAR-T cancer therapies can, in rare cases, induce secondary cancers. The European Medicines Agency (EMA) now recognises this and requires a warning label to be ...

Lundbeck presenterar första behandlingen mot MSA

Danska läkemedelsbolaget Lundbeck har utvecklat antikroppen amlenetug, som kan innebära den första behandling av multipel systematrofi (MSA).

Exploring Molecular Dynamics with Raster Image Correlation Spectroscopy

Case study by ZEISS Microscopy.

EQT säljer Karo Healthcare för 27 miljarder

Riskkapitalbolaget KKR förvärvar det svenska konsumenthälsobolaget Karo Healthcare från EQT.

Vaccinet har räddat 94 miljoner liv – men nu sprids mässlingen igen

En sjukdom som vi trodde hörde till det förgångna ökar nu åter i både Europa och USA. I skuggan av ökad skepsis och minskad vaccintäckning gör mässlingen – som ...

Ny forskning: Fettsyra i ögonen återställde syn hos äldre möss

En enkel ögoninjektion med en speciell fettsyra kunde återställa synförmågan hos äldre möss, enligt en ny studie vid University of California. Resultatet väcker...

He takes over the chairmanship of Karolinska Development

Ben Toogood is appointed as the new chairman of Karolinska Developments.

Carl Borrebaeck – professor and serial entrepreneur with a taste for speed

Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borreb...

Takeover bid is being completed – Japanese company acquires Calliditas

Japanese company Asahi Kasei completes the bid for Calliditas Therapeutics after reaching over 90 percent of the shareholding. Callidita's board has now decided...